Tegsedi FDA Approval History
FDA Approved: Yes (First approved October 5, 2018)
Brand name: Tegsedi
Generic name: inotersen
Dosage form: Injection
Company: Ionis Pharmaceuticals, Inc.
Treatment for: Amyloidogenic Transthyretin Amyloidosis
Tegsedi (inotersen) is an antisense oligonucleotide inhibitor of the transthyretin (TTR) protein for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Development timeline for Tegsedi
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
